Genmab (NASDAQ: GMAB) issues 185 new shares from employee warrants
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S is making a very small capital increase by issuing 185 new shares following the exercise of employee warrants. The shares are subscribed in cash at DKK 1,334.50 per share, providing the company with approximately DKK 0.2 million in proceeds and representing less than 0.001% of its share capital.
After this increase, Genmab’s total nominal share capital is DKK 62,353,252, divided into 62,353,252 ordinary shares with one vote each. The new shares carry standard rights, including dividends from the date of subscription, and will be listed on Nasdaq Copenhagen once registered with the Danish Business Authority.
Positive
- None.
Negative
- None.
Key Figures
New shares issued: 185 shares
Subscription price: DKK 1,334.50 per share
Proceeds to company: DKK 0.2 million
+4 more
7 metrics
New shares issued
185 shares
Capital increase from employee warrant exercise
Subscription price
DKK 1,334.50 per share
Cash subscription price for 185 new shares
Proceeds to company
DKK 0.2 million
Approximate cash raised from warrant exercise
Capital increase proportion
Less than 0.001%
Portion of Genmab’s share capital represented by new shares
Total nominal share capital
DKK 62,353,252
Share capital after the increase
Total shares outstanding
62,353,252 shares
Ordinary shares of nominal DKK 1 each after the increase
Voting rights
62,353,252 votes
One vote per ordinary share after the capital increase
Key Terms
employee warrants, preemption rights, Danish Capital Markets Act, forward looking statements, +1 more
5 terms
employee warrants financial
"Capital Increase in Genmab as a Result of Employee Warrant Exercise"
preemption rights financial
"The increase is effected without any preemption rights for the existing shareholders"
Preemption rights give existing shareholders the first chance to buy newly issued shares so they can keep the same fraction of ownership. Think of it like getting first dibs on extra slices of pizza so your portion of the pie doesn’t shrink. For investors this matters because it protects voting power and value per share by preventing unexpected loss of ownership when a company issues more stock.
Danish Capital Markets Act regulatory
"Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026"
A national law that sets the rules for trading, reporting and oversight of securities and financial markets in Denmark; think of it as the official rulebook that governs how companies, investors and intermediaries must behave when raising capital or trading shares. It matters to investors because it mandates information disclosure, market transparency and conduct standards that reduce fraud, make prices more reliable and protect shareholder rights, helping investors judge risks and make informed decisions.
forward looking statements regulatory
"The Company Announcement contains forward looking statements."
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
antibody–drug conjugates (ADCs) medical
"including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF JUNE 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated June 16, 2026: Capital Increase in Genmab as a Result of Employee Warrant Exercise | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: JUNE 16, 2026
Exhibit 99.1
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
185 shares at DKK 1,334.50.
Proceeds to the Company are approximately DKK 0.2 million. The increase corresponds to less than 0.001%of the Company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,353,252 which is made up of 62,353,252 shares of a nominal value of DKK 1 each, corresponding to 62,353,252 votes.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 31 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Capital Increase in Genmab as a Result of Employee Warrant Exercise
of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 31 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
FAQ
What did Genmab (GMAB) announce in this capital increase filing?
Genmab announced a very small capital increase of 185 new shares from employee warrant exercises. These shares are issued for cash, add about DKK 0.2 million in proceeds, and represent less than 0.001% of the company’s existing share capital.
How much cash does Genmab (GMAB) receive from this warrant exercise?
Genmab receives approximately DKK 0.2 million in cash proceeds from the 185 shares issued. The subscription price per share is DKK 1,334.50, and the capital increase is characterized as less than 0.001% of the company’s share capital.